Literature DB >> 20412876

Persistence of mucosal and systemic immune responses following sublingual immunization.

Donatella R M Negri1, Antonella Riccomi, Dora Pinto, Silvia Vendetti, Alessandra Rossi, Rosella Cicconi, Paolo Ruggiero, Giuseppe Del Giudice, Maria Teresa De Magistris.   

Abstract

The development of mucosal vaccines for prevention of infectious diseases caused by pathogens entering through the mucosal surfaces is an important and challenging objective. To this purpose, we evaluated the efficacy and durability of immune response induced by sublingual immunization with tetanus toxoid (TT) as an antigen in the presence of mucosal adjuvants, such as E. coli Heat-Labile enterotoxin (LT) or the mutant of LT lacking ADP ribosyltransferase activity (LTK63). Both serum anti-TT IgG and mucosal anti-TT IgA antibodies reached a peak after four immunizations and decreased over time, maintaining detectable titers up to 4 months after the last immunization. Similarly, antigen-specific antibody secreting cells in bone marrow and TT-specific CD4+ and CD8+ T cells in draining lymph nodes and spleen were present up to 4 months from the last immunization. Overall, LT-treated mice showed significantly higher responses compared to LTK63 immunized mice. The efficacy and persistence of the immune response induced by sublingual immunization with different adjuvants strongly suggest that this route represents an appealing and promising alternative to the other mucosal routes of vaccine delivery. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412876     DOI: 10.1016/j.vaccine.2010.04.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

2.  Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.

Authors:  L Jean Patterson; Seraphin Kuate; Mara Daltabuit-Test; Qingsheng Li; Peng Xiao; Katherine McKinnon; Janet DiPasquale; Anthony Cristillo; David Venzon; Ashley Haase; Marjorie Robert-Guroff
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

3.  Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.

Authors:  Tara L Martin; Junbae Jee; Eunsoo Kim; Haley E Steiner; Estelle Cormet-Boyaka; Prosper N Boyaka
Journal:  Vaccine       Date:  2017-03-24       Impact factor: 3.641

Review 4.  Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens.

Authors:  Hellen Amuguni; Saul Tzipori
Journal:  Hum Vaccin Immunother       Date:  2012-06-15       Impact factor: 3.452

5.  Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome.

Authors:  D Alecsandru; L Valor; S Sánchez-Ramón; J Gil; J Carbone; J Navarro; J Rodríguez; C Rodríguez-Sainz; E Fernández-Cruz
Journal:  Clin Exp Immunol       Date:  2011-04       Impact factor: 4.330

6.  Porcine Immunoglobulin Fc Fused P30/P54 Protein of African Swine Fever Virus Displaying on Surface of S. cerevisiae Elicit Strong Antibody Production in Swine.

Authors:  Chen Chen; Deping Hua; Jingxuan Shi; Zheng Tan; Min Zhu; Kun Tan; Lilin Zhang; Jinhai Huang
Journal:  Virol Sin       Date:  2020-09-11       Impact factor: 4.327

7.  MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88.

Authors:  C Benito-Villalvilla; C Cirauqui; C M Diez-Rivero; M Casanovas; J L Subiza; O Palomares
Journal:  Mucosal Immunol       Date:  2016-12-14       Impact factor: 7.313

8.  Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.

Authors:  Viviana Buffa; Katja Klein; Lucia Fischetti; Robin J Shattock
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

9.  Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics.

Authors:  M F Lorenzo-Gómez; B Padilla-Fernández; F J García-Criado; J A Mirón-Canelo; A Gil-Vicente; A Nieto-Huertos; J M Silva-Abuin
Journal:  Int Urogynecol J       Date:  2012-07-18       Impact factor: 2.894

10.  Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines.

Authors:  Donatella R M Negri; Alessandra Rossi; Maria Blasi; Zuleika Michelini; Pasqualina Leone; Maria Vincenza Chiantore; Silvia Baroncelli; Gemma Perretta; Andrea Cimarelli; Mary E Klotman; Andrea Cara
Journal:  Retrovirology       Date:  2012-08-22       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.